AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. The company was founded in November 2025 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited. atai Life Sciences was founded in 2018 and became a publicly listed company in 2021. Beckley Psytech, a private company, was founded in 2019. In December 2025, the combined company redomiciled from the Netherlands to the U.S., incorporated in Delaware and headquartered in New York, NY. The company's shares trade on the Nasdaq stock exchange under the ticker symbol ATAI.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ATAI | AtaiBeckley Inc. | 2026-07-02 14:59:55 | 5.2 | 0.33 | 6.67 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATAI | 0002081043 | AtaiBeckley Inc. | US04650F1012 | 529900HOVZ0MXOBQ5Y47 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | C/O ATAI LIFE SCIENCES US, INC. | NEW YORK | NY | 10119 | UNITED STATES | US | 1 929 207 2670 | C/O ATAI LIFE SCIENCES US, INC., NEW YORK, NY, 10119 | C/O ATAI LIFE SCIENCES US, INC., NEW YORK, NY, 10119 | atai Life Sciences Luxembourg S.A. | Biotechnology | 2018 | — | — | https://www.ataibeckley.com/ | 361,300,000 | 365,562,925 | 368,166,674 | AtaiBeckley Inc. is a clinical-stage biotechnology company developing treatments for mental health disorders, including therapies based on psychedelics, entactogens, and related compounds. The company was founded in November 2025 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited. atai Life Sciences was founded in 2018 and became a publicly listed company in 2021. Beckley Psytech, a private company, was founded in 2019. In December 2025, the combined company redomiciled from the Netherlands to the U.S., incorporated in Delaware and headquartered in New York, NY. The company's shares trade on the Nasdaq stock exchange under the ticker symbol ATAI. | 2026-07-02 17:12:45 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 361,300,000 | 361,300,000 | 100 | 364,745,985 | 364,745,985 | 100 |
| 2024 | 172,900,000 | -30,400,000 | -14.9533 | 198,306,455 | 32,280,059 | 19.4427 |
| 2023 | 203,300,000 | -207,800,000 | -50.5473 | 166,026,396 | 15,920 | 0.0096 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Srinivas Rao | Chief Executive Officer | 2025 | 629,200 | 449,878 | — | — | 24,740 | 4,420,555 |
| Gerd Kochendoerfer, Ph.D. | Chief Operating Officer | 2025 | 440,000 | 228,800 | — | — | 10,500 | 2,553,672 |
| Srinivas Rao | Chief Executive Officer | 2024 | 568,333 | 255,777 | — | — | 10,350 | 3,462,560 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 99 |
| Fiscal Year | 2025 |
|---|---|
| Revenue | 4,089,000 |
| Cost Of Revenue | — |
| Gross Profit | 4,089,000 |
| Research And Development Expenses | 53,062,000 |
| General And Administrative Expenses | 65,088,000 |
| Operating Expenses | 648,150,000 |
| Operating Income | -644,061,000 |
| Net Income | -660,047,000 |
| Earnings Per Share Basic | -2.91 |
| Earnings Per Share Diluted | -2.91 |
| Weighted Average Shares Outstanding Basic | 226,532,786 |
| Weighted Average Shares Outstanding Diluted | 226,532,786 |
| Fiscal Year | 2025 |
|---|---|
| Cash And Cash Equivalents | 85,300,000 |
| Marketable Securities Current | — |
| Accounts Receivable | 667,000 |
| Inventories | — |
| Non Trade Receivables | 5,700,000 |
| Other Assets Current | 946,000 |
| Total Assets Current | 275,684,000 |
| Marketable Securities Non Current | — |
| Property Plant And Equipment | 2,166,000 |
| Other Assets Non Current | 1,110,000 |
| Total Assets Non Current | 0 |
| Total Assets | 292,723,000 |
| Accounts Payable | 4,906,000 |
| Deferred Revenue | 1,524,000 |
| Short Term Debt | 135,400,000 |
| Other Liabilities Current | 2,610,000 |
| Total Liabilities Current | 23,479,000 |
| Long Term Debt | 0 |
| Other Liabilities Non Current | 754,000 |
| Total Liabilities Non Current | 0 |
| Total Liabilities | 70,722,000 |
| Common Stock | 3,633,000 |
| Retained Earnings | -1,360,254,000 |
| Accumulated Other Comprehensive Income | -20,926,000 |
| Total Shareholders Equity | 221,874,000 |
| Fiscal Year | 2025 |
|---|---|
| Depreciation And Amortization | 1,012,000 |
| Share Based Compensation Expense | 14,213,000 |
| Other Non Cash Income Expense | 700,000 |
| Change In Accounts Receivable | — |
| Change In Inventories | — |
| Change In Non Trade Receivables | — |
| Change In Other Assets | -691,000 |
| Change In Accounts Payable | -1,695,000 |
| Change In Other Liabilities | -6,237,000 |
| Cash From Operating Activities | -102,675,000 |
| Purchases Of Marketable Securities | 88,945,000 |
| Sales Of Marketable Securities | 0 |
| Acquisition Of Property Plant And Equipment | 901,000 |
| Acquisition Of Business | — |
| Other Investing Activities | 10,000,000 |
| Cash From Investing Activities | -109,127,000 |
| Tax Withholding For Share Based Compensation | — |
| Payments Of Dividends | 0 |
| Issuance Of Common Stock | 252,846,000 |
| Repurchase Of Common Stock | — |
| Issuance Of Long Term Debt | 0 |
| Repayment Of Long Term Debt | — |
| Other Financing Activities | — |
| Cash From Financing Activities | 269,481,000 |
| Change In Cash | 57,795,000 |
| Cash At End Of Period | 85,300,000 |
| Income Taxes Paid | 589,000 |
| Interest Paid | 793,000 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Kochendoerfer Gerd | Chief Operating Officer | 2026-06-26 | 50,000 | A | 50,000 |
| Kochendoerfer Gerd | Chief Operating Officer | 2026-06-26 | 50,000 | D | 0 |
| Kochendoerfer Gerd | Chief Operating Officer | 2026-06-26 | 50,000 | D | 1,400,000 |
| Craig Kevin James | Chief Medical Officer | 2026-06-25 | 9,528 | A | 51,016 |
| Craig Kevin James | Chief Medical Officer | 2026-06-25 | 42,579 | D | 8,437 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| MassMutual Private Wealth & Trust, FSB | 2026-06-30 | 8,111 | 1,539 | 5.2703 |
| Parallel Advisors, LLC | 2026-03-31 | 47,625 | 13,453 | 3.5401 |
| JANUS HENDERSON GROUP PLC | 2026-03-31 | 280,679 | 79,400 | 3.535 |
| Arete Wealth Advisors, LLC | 2026-03-31 | 4,713,035 | 16,395 | 287.4678 |
| ADAR1 Capital Management, LLC | 2026-03-31 | 3,232,877 | 913,242 | 3.54 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| INVESCO EXCHANGE-TRADED FUND TRUST | 2026-04-30 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 29,882 | 124,309.12 | 0.0043 |
| FIDELITY CONCORD STREET TRUST | 2026-04-30 | Fidelity ZERO Total Market Index Fund | FZROX | 99,003 | 411,852.48 | 0.0011 |
| FIDELITY CONCORD STREET TRUST | 2026-04-30 | Fidelity ZERO Extended Market Index Fund | FZIPX | 68,021 | 282,967.36 | 0.0117 |
| FIDELITY SALEM STREET TRUST | 2026-04-30 | Fidelity Flex Small Cap Index Fund | FLXSX | 28,979 | 120,552.64 | 0.0293 |
| J.P. Morgan Exchange-Traded Fund Trust | 2026-04-30 | JPMorgan BetaBuilders U.S. Small Cap Equity ETF | BBSC | 112,661 | 468,669.76 | 0.064 |